Accordingly, abnormal number and function of CD4+Foxp3+ Treg cells have been reported in RA and SLE, and it has been proposed that the autoimmune responses observed in these patients could be controlled by the clinical use of Treg cells to treat these conditions [4–6]. Here, FOXP3 is linked to rheumatoid arthritis.